Converting from Basaglar 40 units BID to Tresiba
Start Tresiba at 64 units once daily (80% of the total daily Basaglar dose of 80 units).
Dosing Rationale
Your patient is currently taking Basaglar (insulin glargine U-100) 40 units twice daily, for a total daily dose of 80 units. When converting from twice-daily basal insulin to once-daily Tresiba (insulin degludec), the FDA-approved approach is clear:
For pediatric patients switching from twice-daily basal insulin to Tresiba, start at 80% of the total daily long or intermediate-acting insulin dose 1. While this specific guidance is labeled for pediatric patients in the prescribing information, the same principle applies to adults on split-dose regimens to minimize hypoglycemia risk during the transition.
Why 80% Conversion?
The dose reduction is critical because:
- Tresiba has a longer half-life (approximately 25 hours) compared to Basaglar (approximately 12 hours), leading to more stable insulin levels with less peak-trough variation
- Risk mitigation for hypoglycemia during the transition period as steady-state levels are achieved over several days 1
- The FDA label explicitly warns that changes in insulin regimen may affect glycemic control and predispose to hypoglycemia, requiring close medical supervision 1
Practical Implementation
Initial Conversion
- Starting dose: 64 units Tresiba once daily (80% of 80 units)
- Administer at the same time each day (unlike adults, pediatric dosing requires consistent timing) 1
- Can be given at any time of day, but consistency is key
Monitoring Requirements
- Increase frequency of blood glucose monitoring during the transition 1
- Monitor fasting plasma glucose closely
- Watch for hypoglycemia, particularly in the first week as steady-state is achieved
Titration After Conversion
Once stable on Tresiba, titrate based on fasting glucose goals:
- Adjust every 3-4 days as needed 1
- Increase by 2-4 units once or twice per week until fasting plasma glucose reaches target (typically 80-130 mg/dL) 2, 3
- The 2025 ADA guidelines recommend evidence-based titration algorithms, such as increasing 2 units every 3 days to reach fasting glucose goals without hypoglycemia 2
Important Caveats
Why Not 1:1 Conversion?
While some clinicians might consider unit-for-unit conversion (80 units), this approach carries higher hypoglycemia risk given Tresiba's pharmacokinetic profile. The research supports that dose adjustments are often needed when switching between basal insulins 4, and starting conservatively is safer.
If Hypoglycemia Occurs
- Determine the cause
- If no clear reason identified, reduce dose by 10-20% 2, 1
- Ensure patient is not injecting into areas of lipodystrophy, which can cause erratic absorption
Unique Advantage of Tresiba
Unlike Basaglar, adults on Tresiba can dose flexibly (not necessarily same time daily) as long as at least 8 hours elapse between doses 1. However, for optimal glycemic control, consistent timing is still preferred.
Cost Considerations
The 2025 ADA guidelines emphasize that choice of basal insulin should be based on person-specific considerations, including cost 2. Ensure insurance coverage is verified before switching, as Tresiba may have different formulary status than Basaglar.